Soligenix, Inc.
(NASDAQ : SNGX)

( )
SNGX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.79%171.561.2%$575.26m
CELGCelgene Corporation
-0.75%88.951.2%$554.24m
GILDGilead Sciences, Inc.
-0.99%73.700.9%$441.10m
BIIBBiogen Inc.
-1.13%263.021.2%$436.72m
REGNRegeneron Pharmaceuticals, Inc.
-0.50%314.252.7%$242.24m
INCYIncyte Corporation
-0.90%68.432.5%$236.48m
VRTXVertex Pharmaceuticals Incorporated
-0.88%158.151.9%$224.32m
ALXNAlexion Pharmaceuticals, Inc.
-3.54%107.782.0%$215.70m
NKTRNektar Therapeutics
-4.37%86.216.0%$196.49m
ILMNIllumina, Inc.
-0.50%244.603.5%$185.23m
AAgilent Technologies, Inc.
-0.63%67.541.5%$152.87m
ALNYAlnylam Pharmaceuticals, Inc
1.34%97.489.8%$137.98m
BLUEBluebird Bio, Inc.
0.00%170.5015.8%$135.45m
EXASExact Sciences Corporation
1.54%47.5225.7%$108.85m
BMRNBioMarin Pharmaceutical Inc.
-1.58%82.304.4%$107.66m

Company Profile

Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments. The BioTherapeutics segment involves in the development of photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. The Vaccines or BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.